Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia

Future Medicinal Chemistry

Volumn 5, Issue 13, 2013, Pages 1491-1508

  Weïwer, Michel ^a   Lewis, Michael C ^a   Wagner, Florence F ^a   Holson, Edward B ^a  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 [3 (3 FLUOROPHENYL) 3 OXO 1 PROPENYL] 1 METHYL 1H PYRROL 2 YL]ACRYLOHYDROXAMIC ACID; 5 ARYL ISOXAZOLE DERIVATIVE; ALKANOIC ACID; ARIPIPRAZOLE; BRD 9757; BUTYRIC ACID; CHLORPROMAZINE; CLOZAPINE; DEPSIPEPTIDE; ENTINOSTAT; HALOPERIDOL; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LURASIDONE; MI 192; MOCETINOSTAT; NAPHTHOQUINONE; NEUROLEPTIC AGENT; RGFP 136; RGFP 966; RICOLINOSTAT; ROMIDEPSIN; TACEDINALINE; THIOL; TRICHOSTATIN A; TUBACIN; TUBASTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VORINOSTAT;

AGRANULOCYTOSIS; BLOOD BRAIN BARRIER; CHROMATIN STRUCTURE; COGNITION; COGNITIVE DEFECT; COMPETITIVE INHIBITION; DNA SEQUENCE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANIMALS; DRUG DISCOVERY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PROTEIN ISOFORMS; SCHIZOPHRENIA;

EID: 84884260938     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.141     Document Type: Review

References (88)

1. Desbonnet L, O'Tathaigh CMP, Waddington JL. Modeling schizophrenia: Uncovering novel therapeutic targets. Expert Rev. Clin. Pharmacol. 5(6), 667-676 (.2012
2. Ibrahim HM, Tamminga CA. Treating impaired cognition in schizophrenia. Curr. Pharm. Biotechnol. 13(8), 1587-1594 (.2012
3. Chuang D-M, Leng Y, Marinova Z, Kim H-J, Chiu C-T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32(11), 591-601 (.2009
4. Fass DM, Kemp MM, Schroeder FA, Wagner FF, Wang Q, Holson EB. Histone acetylation and deacetylation. Epigenetic Regulation Epigenomics 1, 515-561 (.2012
5. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (.2006
6. Broide RS, Redwine JM, Aftahi N, Young W, Bloom FE, Winrow CJ. Distribution of histone deacetylases 1-11 in the rat brain. J. Mol. Neurosci. 31(1), 47-58 (.2007
7. Hasan A, Mitchell A, Schneider A, Halene T, Akbarian S. Epigenetic dysregulation in schizophrenia: Molecular and clinical aspects of histone deacetylase inhibitors. Eur. Arch. Psychiatry Clin. Neurosci. 263(4), 273-284 (.2013
8. Kim T, Park JK, Kim H-J, Chung J-H, Kim JW. Association of histone deacetylase genes with schizophrenia in Korean population. Psychiatry Res. 178(2), 266-269 (.2010
9. Tam GWC, Van De Lagemaat LN, Redon R et al. Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochem. Soc. Trans. 38(2), 445-451 (.2010
10. Guidotti A, Auta J, Davis JM et al. Decrease in reelin and glutamic acid decarboxylase67 (.GAD67) expression in schizophrenia and bipolar disorder a postmortem brain study. Arch. Gen. Psychiatry 57(11), 1061-1069 (.2000
11. Simonini MV, Camargo LM, Dong E et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl Acad. Sci. USA 103(5), 1587-1592 (.2006
12. Gavin DP, Rosen C, Chase K, Grayson DR, Tun N, Sharma RP. Dimethylated lysine 9 of histone 3 is elevated in schizophrenia and exhibits a divergent response to histone deacetylase inhibitors in lymphocyte cultures. J. Psychiatry Neurosci. 34(3), 232-237 (.2009
13. Kurita M, Holloway T, Garcia-Bea A et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci. 15(9), 1245-1254 (.2012
14. Calabrese F, Luoni A, Guidotti G, Racagni G, Fumagalli F, Riva MA. Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid. Psychopharmacology 226(1), 101-112 (.2013
15. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 10(3), 209-219 (.2011
16. Buckley Peter F, Miller Brian J, Lehrer Douglas S, Castle David J. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 35(2), 383-402 (.2009
17. Yamawaki Y, Fuchikami M, Morinobu S, Segawa M, Matsumoto T, Yamawaki S. Antidepressant-like effect of sodium butyrate (.HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J. Biol. Psychiatry 13(6), 458-467 (.2012
18. Covington HE 3rd, Vialou VF, LaPlant Q, Ohnishi YN, Nestler EJ. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci. Lett. 493(3), 122-126 (.2011
19. Covington HE 3rd, Maze I, La Plant QC et al. Antidepressant actions of histone deacetylase inhibitors. J. Neurosci. 29(37), 11451-11460 (.2009
20. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9(4), 519-525 (.2006
21. Fukada M, Hanai A, Nakayama A et al. Loss of deacetylation activity of Hdac6 affects emotional behavior in mice. PLoS ONE 7(2), e30924 (.2012
22. Lynch MA. Long-term potentiation and memory. Physiol. Rev. 84(1), 87-136 (.2004
23. Levenson JM, O'riordan KJ, Brown KD, Trinh MA, Molfese DL, Sweatt JD. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279(39), 40545-40559 (.2004
24. Haettig J, Stefanko DP, Multani ML, Figueroa DX, Mcquown SC, Wood MA. HDAC inhibition modulates hippocampus-dependent long-term memory for object location in a CBP-dependent manner. Learn. Mem. 18(2), 71-79 (.2011
25. Korzus E, Rosenfeld MG, Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42(6), 961-972 (.2004
26. Lopez-Atalaya JP, Gervasini C, Mottadelli F et al. Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome. J. Med. Gen. 49(1), 66-74 (.2012
27. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai L-H. Recovery of learning and memory is associated with chromatin remodelling. Nature 447(7141), 178-182 (.2007
28. Kilgore M, Miller CA, Fass DM et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of alzheimer's disease. Neuropsychopharmacology 35(4), 870-880 (.2010
29. Ricobaraza A, Cuadrado-Tejedor M, Perez- Mediavilla A, Frechilla D, Del Rio J, Garcia- Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an alzheimer's disease mouse model. Neuropsychopharmacology 34(7), 1721-1732 (.2009
30. Graeff J, Rei D, Guan J-S et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483(7388), 222-226 (.2012
31. Sandner G, Host L, Angst M-J, Guiberteau T, Guignard B, Zwiller J. The HDAC inhibitor phenylbutyrate reverses effects of neonatal ventral hippocampal lesion in rats. Front. Psychiatry 1, 153 (.2011
32. Bahari-Javan S, Maddalena A, Kerimoglu C et al. HDAC1 regulates fear extinction in mice. J. Neurosci. 32(15), 5062-5073 (.2012
33. Guan J-S, Haggarty SJ, Giacometti E et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459(7243), 55-60 (.2009
34. McQuown SC, Barrett RM, Matheos DP et al. HDAC3 is a critical negative regulator of long-term memory formation. J. Neuroscience 31(2), 764-774 (.2011
35. Malvaez M, Mcquown Susan C, Rogge George A et al. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc. Natl Acad. Sci. USA 110(7), 2647-2652 (.2013
36. Kim M-S, Akhtar MW, Adachi M et al. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J. Neurosci. 32(32), 10879-10886 (.2012
37. Govindarajan N, Rao P, Burkhardt S et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol. Med. 5(1), 52-63 (.2013
38. Finnin MS, Donigian JR, Cohen A et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749), 188-193 (.1999
39. Gupta P, Reid RC, Iyer A, Sweet MJ, Fairlie DP. Towards isozyme-selective HDAC inhibitors for interrogating disease. Curr. Top. Med. Chem. 12(14), 1479-1499 (.2012
40. Bieliauskas AV, Pflum MKH. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 37(7), 1402-1413 (.2008
41. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: Can we see the forest for the trees? Cell. Mol. Life Sci. 64(16), 2090-2103 (.2007
42. Kavanaugh SA, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am. J. Health Syst. Pharm. 67(10), 793-797 (.2010
43. Moradei OM, Mallais TC, Frechette S et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J. Med. Chem. 50(23), 5543-5546 (.2007
44. Nielsen TK, Hildmann C, Dickmanns A, Schwienhorst A, Ficner R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol. 354(1), 107-120 (.2005
45. Somoza JR, Skene RJ, Katz BA et al. Structural snapshots of human HDAC8 provide insights into the Class I histone deacetylases. Structure 12(7), 1325-1334 (.2004
46. Methot JL, Chakravarty PK, Chenard M et al. Exploration of the internal cavity of histone deacetylase (.HDAC) with selective HDAC1/HDAC2 inhibitors (.SHI-1:2). Bioorg. Med. Chem. Lett. 18(3), 973-978 (.2008
47. Witter DJ, Harrington P, Wilson KJ et al. Optimization of biaryl selective HDAC1&2 inhibitors (.SHI-1:2). Bioorg. Med. Chem. Lett. 18(2), 726-731 (.2008
48. Heidebrecht RW Jr, Chenard M, Close J et al. Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (.SHI-1:2). Bioorg. Med. Chem. Lett. 19(7), 2053-2058 (.2009
49. Bressi JC, Jennings AJ, Skene R et al. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2- aminophenyl)benzamides. Bioorg. Med. Chem. Lett. 20(10), 3142-3145 (.2010
50. Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of Class I histone deacetylases. J. Biol. Chem. 283(51), 35402-35409 (.2008
51. Durham B. Novel histone deacetylase (.HDAC) inhibitors with improved selectivity for HDAC2 and 3 protect against neural cell death. Biosci. Horizons 5(1), hzs003 (.2012
52. Boissinot M, Inman M, Hempshall A et al. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192. Leukemia Res. 36(10), 1304-1310 (.2012
53. Silvestri L, Ballante F, Mai A, Marshall GR, Ragno R. Histone deacetylase inhibitors: Structure-based modeling and isoform- selectivity prediction. J. Chem. Inf. Model. 52(8), 2215-2235 (.2012
54. Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. Use of the nitrile oxide cycloaddition (.NOC) reaction for molecular probe generation: A new class of enzyme selective histone deacetylase inhibitors (.HDACIs) showing picomolar activity at HDAC6. J. Med. Chem. 51(15), 4370-4373 (.2008
55. Chen Y, He R, Chen Y, D'Annibale MA, Langley B, Kozikowski AP. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: Identification of some HDAC3-selective inhibitors. ChemMedChem 4(5), 842-852 (.2009
56. Rai M, Soragni E, Chou CJ et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS ONE 5(1), e8825 (.2010
57. Beconi M, Aziz O, Matthews K et al. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. PLoS ONE 7(9), e44498 (.2012
58. Dallavalle S, Pisano C, Zunino F. Development and therapeutic impact of HDAC6-selective inhibitors. Biochem. Pharmacol. 84(6), 756-765 (.2012
59. Inks ES, Josey BJ, Jesinkey SR, Chou CJ. A novel class of small molecule inhibitors of HDAC6. ACS Chem. Biol. 7(2), 331-339 (.2012
60. Dehmel F, Weinbrenner S, Julius H et al. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles. J. Med. Chem. 51(13), 3985-4001 (.2008
61. Kozikowski AP, Chen Y, Gaysin AM, Savoy DN, Billadeau DD, Kim KH. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem 3(3), 487-501 (.2008
62. Suzuki T, Kouketsu A, Itoh Y et al. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem. 49(16), 4809-4812 (.2006
63. Itoh Y, Suzuki T, Kouketsu A et al. Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J. Med. Chem. 50(22), 5425-5438 (.2007
64. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (.HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100(8), 4389-4394 (.2003
65. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 10(5), 383-396 (.2003
66. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132(31), 10842-10846 (.2010
67. Auzzas L, Larsson A, Matera R et al. Non-natural macrocyclic inhibitors of histone deacetylases: Design, synthesis, and activity. J. Med. Chem. 53(23), 8387-8399 (.2010
68. Chen Y, Lopez-Sanchez M, Savoy DN, Billadeau DD, Dow GS, Kozikowski AP. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J. Med. Chem. 51(12), 3437-3448 (.2008
69. Schaefer S, Saunders L, Eliseeva E et al. Phenylalanine-containing hydroxamic acids as selective inhibitors of Class IIb histone deacetylases (.HDACs). Bioorg. Med. Chem. 16(4), 2011-2033 (.2008
70. Wagner FF, Olson DE, Gale JP et al. Potent and selective inhibition of histone deacetylase 6 (.HDAC6) does not require a surface-binding motif. J. Med. Chem. 56(4), 1772-1776 (.2013
71. Kalin JH, Butler KV, Akimova T, Hancock WW, Kozikowski AP. Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells. J. Med. Chem. 55(2), 639-651 (.2012
72. Santo L, Hideshima T, Kung AL et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119(11), 2579-2589 (.2012
73. Valente S, Tardugno M, Conte M et al. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: Apoptotic induction and cytodifferentiation activity. ChemMedChem 6(4), 698-712 (.2011
74. Mai A, Massa S, Pezzi R et al. Class II (.IIa)- selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (.aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 48(9), 3344-3353 (.2005
75. Mai A, Massa S, Pezzi R, Rotili D, Loidl P, Brosch G. Discovery of (.aryloxopropenyl) pyrrolyl hydroxyamides as selective inhibitors of Class IIa histone deacetylase homologue HD1-A. J. Med. Chem. 46(23), 4826-4829 (.2003
76. Mai A, Valente S, Nebbioso A et al. New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme- and cell-based investigations. Int. J. Biochem. Cell Biol. 41(1), 235-247 (.2009
77. Tessier P, Smil DV, Wahhab A et al. Diphenylmethylene hydroxamic acids as selective Class IIa histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 19(19), 5684-5688 (.2009
78. Lobera M, Madauss KP, Pohlhaus DT et al. Selective Class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat. Chem. Biol. 9(5), 319-325 (.2013
79. Jayathilaka N, Han A, Gaffney KJ et al. Inhibition of the function of Class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 40(12), 5378-5388 (.2012
80. Bottomley MJ, Lo Surdo P, Di Giovine P et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 283(39), 26694-26704 (.2008
81. Schuetz A, Min J, Allali-Hassani A et al. Human HDAC7 harbors a Class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283(17), 11355-11363 (.2008
82. Palmieri D, Lockman PR, Thomas FC et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin. Cancer Res. 15(19), 6148-6157 (.2009
83. Hooker JM, Kim SW, Alexoff D et al. Histone deacetylase inhibitor MS-275 exhibits poor brain penetration: Pharmacokinetic studies of [11C]MS-275 using positron emission tomography. ACS Chem. Neurosci. 1(1), 65-73 (.2010
84. Xu C, Soragni E, Jacques V, Rusche JR, Gottesfeld JM. Improved histone deacetylase inhibitors as therapeutics for the neurodegenerative disease Friedreich's ataxia: A new synthetic route. Pharmaceuticals 4, 1578-1590 (.2011
85. Riva L, Blaney SM, Dauser R et al. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (.N-acetyldinaline) in the nonhuman primate. Clin. Cancer Res. 6(3), 994-997 (.2000
86. Fass DM, Shah R, Ghosh B et al. Short-chain HDAC inhibitors differentially affect vertebrate development and neuronal chromatin. ACS Med. Chem. Lett. 2(1), 39-42 (.2011
87. Bradner JE, West N, Grachan ML et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6(3), 238-243 (.2010
88. Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharm. Design 14(6), 505-528 (.2008)